因此，仍然需要探索新的B-ALL治疗方案。 Blinatumomab（贝林妥欧单抗）是一种双特异性抗体，靶向B系细胞表面CD19抗原的同时让CD3+ T细胞重定向进行CD19 ...

Following is a transcript of her remarks: ECOG-ACRIN E1910 is a [study] that we recently published that looked at the role of blinatumomab in consolidation therapy in adults in newly diagnosed ALL.

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the addition of blinatumomab to standard chemotherapy for pediatric B-cell ...

12, 2024 (HealthDay News) -- For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for relapse, adding blinatumomab to combination ...

Median disease-free survival (DFS) at 3 years improved from 87.9% with chemotherapy alone to 96.0% with the blinatumomab consolidation. DFS improved significantly in patients with a National ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

Next, he turns to a study of blinatumomab (BLIN) in pediatric ALL, which was presented during the ASH plenary session. BLIN improved outcomes for children with standard-risk B-cell ALL (B-ALL ...

The breakthrough, described in a New England Journal of Medicine paper and presented at a conference in mid-December, is called blinatumomab, an immunotherapy drug delivered to patients over a 28 ...

The trial, which included over two hundred sites across four countries, combined standard chemotherapy with two cycles of blinatumomab, an immunotherapy already used for children with relapsed B-ALL.

“The clinical trial closed early because the results were clear: Those not receiving the drug did significantly worse than those that were treated with blinatumomab,” said Dr. Gore.

They show that adding the bi-specific T-cell engaging antibody blinatumomab to standard chemotherapy significantly improves three-year disease-free survival for children who have been newly ...